据BusinessWire消息，专注于精准医疗AI算法开发的初创公司Zephyr AI近日宣布，已成功完成了一轮1.11亿美元的A轮融资。此轮融资由知名投资机构Revolution Growth领投，同时得到了制药巨头礼来公司、社会企业家Jeff Skoll以及EPIQ Capital Group等重量级投资者的积极参与。
Zephyr AI公司致力于研发快速且可解释的人工智能解决方案，以推动医疗行业的精准医疗进程。通过其创新技术，Zephyr AI有望为医生和医疗机构提供更精确的诊断工具和个性化的治疗方案，从而提升医疗服务的效率和质量。
本次融资的成功，不仅彰显了市场对Zephyr AI技术潜力的认可，也为公司进一步拓展研发和市场布局提供了强大的资金支持。Zephyr AI表示，将利用这笔资金加速AI算法的研发，加强与医疗行业的合作，并扩大全球市场影响力。
礼来公司的参与，预示着制药领域对AI技术应用于精准医疗的浓厚兴趣。通过与Zephyr AI的合作，双方有望在药物研发和患者治疗方面实现更深度的个性化和精准化。
Zephyr AI的创始人兼首席执行官在声明中表示：“我们非常荣幸能得到这些杰出投资者的信任和支持。这笔资金将加速我们实现人工智能在医疗领域的革命性应用，为全球患者带来更高效、更个性化的医疗服务。”
此次A轮融资的完成，无疑为Zephyr AI在精准医疗AI领域的领先地位奠定了坚实基础，同时也为医疗科技行业的未来发展注入了新的活力。
英语如下：
**News Title:** “Zephyr AI, a Precision Medicine AI Company, Secures $110M in Series A Funding Led by Revolution Growth”
**Keywords:** Zephyr AI, Precision Medicine, Series A Funding
**News Content:**
**Title:** Zephyr AI, a Precision Medicine AI Startup, Closes $110M Series A Financing, Paving the Way for Medical Technology Innovation
According to BusinessWire, Zephyr AI, a startup focused on developing AI algorithms for precision medicine, recently announced the successful completion of a $110 million Series A funding round. The round was led by prominent investor Revolution Growth, with significant participation from pharmaceutical giant Eli Lilly, social entrepreneur Jeff Skoll, and EPIQ Capital Group.
Zephyr AI is dedicated to creating fast and explainable AI solutions to advance the field of precision medicine. By leveraging its innovative technology, the company aims to provide doctors and healthcare institutions with more accurate diagnostic tools and personalized treatment plans, enhancing the efficiency and quality of healthcare services.
The successful funding round underscores market confidence in Zephyr AI’s technological potential and provides the financial backing needed for the company to expand its R&D and market presence. Zephyr AI plans to utilize the funds to accelerate AI algorithm development, deepen collaborations within the healthcare industry, and amplify its global footprint.
Eli Lilly’s involvement signals a strong interest in AI applications for precision medicine within the pharmaceutical sector. Through its partnership with Zephyr AI, the two companies aim to enhance drug development and patient treatment with greater personalization and precision.
The founder and CEO of Zephyr AI remarked in a statement, “We are honored to have the support of these exceptional investors. This funding will accelerate our mission to revolutionize AI applications in healthcare, delivering more efficient and personalized services to patients worldwide.”
The conclusion of this Series A funding solidifies Zephyr AI’s leading position in the precision medicine AI landscape and injects new vitality into the future of the medical technology industry.
【来源】https://www.businesswire.com/news/home/20240312475536/en/Zephyr-AI-Raises-111-Million-in-Series-A-Financing
Views: 1